C-Bridge Capital
18
70M
5
2.00
6
0.38
2
- Stages of investment
- Areas of investment
Summary
C-Bridge Capital appeared to be the VC, which was created in 2014. The fund was located in Asia if to be more exact in China. The main department of described VC is located in the Shanghai.
The overall number of key employees were 11.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the C-Bridge Capital, startups are often financed by Thomas, McNerney & Partners, Tasly Pharmaceutical, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Tasly Pharmaceutical, Qianhai Fund of Funds, WTT Investment. In the next rounds fund is usually obtained by Tasly Pharmaceutical, Xiamen Venture Capital, WTT Investment.
Opposing the other organizations, this C-Bridge Capital works on 12 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2018. When the investment is from C-Bridge Capital the average startup value is 100-500 millions dollars. Speaking about the real fund results, this VC is 47 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
Among the most popular portfolio startups of the fund, we may highlight Ascletis, I-Mab Biopharma, CMAB BioPharm. The fund has specific favorite in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there are Medical, Product Research. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 18
- Lead investments
- 6
- Exits
- 2
- Rounds per year
- 2.00
- Follow on index
- 0.38
- Investments by industry
- Health Care (5)
- Biotechnology (4)
- Medical (4)
- Pharmaceutical (2)
- Product Research (2) Show 4 more
- Investments by region
-
- China (6)
- United States (2)
- Peak activity year
- 2018
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 60M
- Group Appearance index
- 0.25
- Strategy success index
- 0.33
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Leo Summit | 05 Dec 2022 | Biotechnology, Manufacturing, Medical, Life Science | Seed | Beijing, Changping, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.